Estrella Immunopharma, Inc. (ESLA) — Institutional Holders, Q2 2026
15 institutional investment managers reported a ESLA position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $5.0M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
ESLA in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- VANGUARD CAPITAL MANAGEMENTAdded · +34,383 sh+$35.8K
- NORTHERNAdded · +15,237 sh+$15.8K
- BlackRockAdded · +12,143 sh+$12.6K
- US BANCORP \DE\Added · +3,096 sh+$3.2K
- BARCLAYS PLCNew · +126 sh+$131.00
Biggest sellers
- WELLS FARGO & COMPANYSold out · -264,388 sh-$275.0K
- ARMISTICE CAPITALTrimmed · -123,780 sh-$128.7K
- RENAISSANCE TECHNOLOGIESTrimmed · -23,695 sh-$24.6K
- GEODE CAPITAL MANAGEMENTTrimmed · -16,164 sh-$16.8K
- UBS Group AGTrimmed · -13,358 sh-$13.9K
ESLA 13F holders ranked 1–15 of 15
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL#1 · 3,975,220 sh | 3,975,220 | $4.1M | 0.05% | -3.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 416,852 sh | 416,852 | $433.5K | 0.00% | +9.0% |
| 3 | GEODE CAPITAL MANAGEMENT#3 · 141,321 sh | 141,321 | $147.0K | 0.00% | -10.3% |
| 4 | VANGUARD FIDUCIARY#4 · 64,921 sh | 64,921 | $67.5K | 0.00% | 0.0% |
| 5 | BlackRock#5 · 52,033 sh | 52,033 | $54.1K | 0.00% | +30.4% |
| 6 | STATE STREET#6 · 43,252 sh | 43,252 | $45.0K | 0.00% | 0.0% |
| 7 | RENAISSANCE TECHNOLOGIES#7 · 39,100 sh | 39,100 | $40.7K | <0.01% | -37.7% |
| 8 | NORTHERN#8 · 34,861 sh | 34,861 | $36.3K | 0.00% | +77.6% |
| 9 | US BANCORP \DE\#9 · 20,000 sh | 20,000 | $20.8K | 0.00% | +18.3% |
| 10 | Tower Research Capital (TRC)#10 · 3,308 sh | 3,308 | $3.4K | <0.01% | -31.9% |
| 11 | UBS Group AG#11 · 1,721 sh | 1,721 | $1.8K | 0.00% | -88.6% |
| 12 | TORONTO DOMINION BANK#12 · 1,089 sh | 1,089 | $1.1K | 0.00% | 0.0% |
| 13 | WOLVERINE ASSET MANAGEMENT#13 · 468 sh | 468 | $487.00 | 0.00% | 0.0% |
| 14 | BARCLAYS PLC#14 · 126 sh | 126 | $131.00 | 0.00% | New |
| 15 | Caitong International Asset Management , Ltd#15 · 2 sh | 2 | $2.00 | 0.00% | New |
Funds that sold out of ESLA in Q2 2026 (3)
Held ESLA at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| WELLS FARGO & COMPANY264,388 sh | 264,388 | $280.3K |
| ROYAL BANK OF CANADA6,600 sh | 6,600 | $7.0K |
| MORGAN STANLEY1 sh | 1 | $1.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.